



File View Edit Tools Window Help

Drafts

- BRS:
- BRS:
- BRS: ("s,r" or "(sr "ls,3r") same (formoterol or foradil or eformot
- ISNR:
- ISNR:
- BRS:
- ISNR:
- BRS: 1 and 3
- BRS: 1 adn 3
- BRS: (vitamin\$1 or ascorb\$ or tocopheryl or tocopherol) same thicke
- ISNR:
- BRS:
- ISNR:

Pending

Active

- L1: (5596) apatite\$1 or hydroxyapatite\$1
- L3: (5892) embol\$
- L5: (55) 1 and 3

Failed

- (0) \$benzoate\$1
- (0) 13 and 9'
- (0) \$apatite\$1

Saved

Favorites

Tagged

UDC

Queue

Trash

US-PAT-NO: 6123923  
DOCUMENT-IDENTIFIER: US 6123923 A  
TITLE: Optoacoustic contrast agents and methods for their use  
DATE-ISSUED: September 26, 2000  
US-CL-CURRENT: 424/9.52, 424/450, 424/9.1, 424/9.2, 424/9.3, 424/9.6, 514/410  
APPL-NO: 8/ 993165  
DATE FILED: December 18, 1997  
DEPR:  
"Clathrate" refers to a solid, semi-porous or porous particle which may be associated with vesicles. In a preferred form, the clathrates may form a cage-like structure containing cavities which comprise one or more vesicles bound to the clathrate, if desired. A stabilizing material may, if desired, be associated with the clathrate to promote the association of the vesicle with the clathrate. Clathrates may be formulated from, for example, porous ~~apatite~~ such as calcium ~~hydroxyapatite~~ and precipitates of polymers and metal ions, such as alginic acid precipitated with calcium salts.  
DEPR:  
A targeting ligand directed toward thrombotic material in the plaque may be used to differentiate between active and inactive regions of atherosclerotic plaque. Active plaques in the process of generating thrombi are more dangerous as these plaques may ultimately occlude a vessel or result in ~~embol~~. In this regard, in addition to low molecular weight heparin fragments, other targeting ligands, such as, for example, anti-fibrin antibody, tissue plasminogen activator (t-PA), anti-thrombin antibody and fibrin antibodies directed to platelet activation fractions, may be used to target active plaque with evolving clots. Preferred targeting ligands are those which will target a plasma membrane associated GPIIb/IIIa in activated platelets in addition to targeting P-selectin, and an antibody or associated antibody fragment directed to GPIIb/IIIa. The present invention is also useful for detecting regions of acute myocardial infarction. By attaching anti-myosin (particularly cardiomyosin) antibody or anti-actin antibodies to the lipids, polymers or stabilizing

U	1	Document ID	Issue Date	Pages	Title	Current OR	Current IRef	Retrieval C	Inventor	B	C	D	E	F	G	H	I	J	K	L	M	N	O	P	Q	R	S	T	U	V	W	X	Y	Z
1	<input checked="" type="checkbox"/>	US 6156540 A	20001205	19	Thrombin inhibitor	435/69.2	435/243 ; 435/320.1 ; 435/325		Rosen, Craig A. ; et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2	<input checked="" type="checkbox"/>	US 6146657 A	20001114	24	Gas-filled lipid spheres for use in diagnostic and therapeutic	424/450	424/489 ; 424/502 ; 424/9.32		Unger, Evan C. ; et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3	<input checked="" type="checkbox"/>	US 6139819 A	20001031		Targeted contrast agents for diagnostic and therapeutic use	424/9.52	424/450 ; 424/9.51		Unger, Evan C. ; et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
4	<input checked="" type="checkbox"/>	US 6133422 A	20001017		Thrombin inhibitor	530/350	435/13 ; 435/243 ; 435/69.2		Rosen, Craig A. ; et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5	<input checked="" type="checkbox"/>	US 6123923 A	20000926	81	Optoacoustic contrast agents and methods for their use	424/9.52	424/450 ; 424/9.1 ; 424/9.2		Unger, Evan C. ; et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6	<input checked="" type="checkbox"/>	US 6120751 A	20000919		Charged lipids and uses for the same	424/9.51	264/4 ; 264/4.1 ; 424/450		Unger, Evan C.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
7	<input checked="" type="checkbox"/>	US 6090800 A	20000718		Lipid soluble steroid	514/180	552/574		Unger, Evan C.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Unger

File View Edit Tools Window Help

Drafts

- BRB: ("s,r" or "(sr "ls,3r") same (formoterol or foradil or eformot
- ISNR:
- BRB:
- ISNR:
- BRB: 1 and 3
- BRB: 1 adn 3
- BRB:
- BRB: (vitaminS1 or ascorbS or tocopheryl or tocopherol) same thicke
- ISNR:
- BRB:
- ISNR:

Pending

Active

- L1: (5596) apatiteS1 or hydroxyapatiteS1
- L3: (5892) embolS
- L5: (53) 1 and 3

Failed

- (U) SbenzoateS1
- (U) 13 and 9'
- (U) SapatiteS1

Saved

Favorites

Tagged

UDC

Queue

Trash

US-PAT-NO: 5599291  
DOCUMENT-IDENTIFIER: US 5599291 A  
TITLE: Softening expanding ureteral stent  
DATE-ISSUED: February 4, 1997  
US-CL-CURRENT: 604/8, 604/264, 604/544  
APPL-NO: 8/ 000274  
DATE FILED: January 4, 1993  
DEPR:  
Mineralization, or more specifically calcification, particularly calcium formation, can be inhibited by various chemicals. These chemicals can be incorporated into stents by the various methods referenced above. Anti-calcification chemicals or additives are known in the art and include certain diphosphonates, especially ethanehydroxy diphosphonate (EHDP), certain metal ions, especially aluminum and iron and alpha amino oleic acid derivatives to name but a few. For example, hydroxyethylidene biphosphonic acid dispersed in polyurethane (PU) articles inhibits calcification of the polymer and of the surrounding tissue and EHDP can diffuse through PU membranes and inhibit calcification of tissue. Aluminum or iron ions and oleic acid compounds have all been reported to reduce calcification of bioprosthetic porcine heart valves.

ORPL:  
Experimental ~~Embolic~~ of Hypan-R Into Rabbit Kidneys--Daniel P. Link--Abstract from Sixteenth Annual Meeting of the Society of Cardiovascular and Interventional Radiology--Interventional Radiology 1991--Feb. 16-21, 1991.

ORPL:  
Hypan-R, A Promising New ~~Embolic~~ Agent--Possibilities & Capabilities--Dr. Daniel P. Link, Dr. Blashka, Dr. Tesluk and Dr. Gu--Abstract from Meeting of Cardiovascular and Interventional Radiological Society of Europe--Society of Cardiovascular and Interventional Radiology--Joint Meeting, Oslo, May 13-16, 1991.

U	Document ID	Issue Date	Pages	Title	Current OR	Current IRef	Retrieval C	Inventor	B	C	P	3		
25	US 5665570 A	19970909		Antibody-encoding recombinant DNA and its use	435/69.6	435/252.3 ; 435/320.1 ; 435/69.1		Yamagata, Hideo , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
26	US 5656211 A	19970812	44	Apparatus and method for making gas-filled vesicles of optimal size	264/4.1	264/4.3 ; 424/489 ; 424/490		Unger, Evan , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
27	US 5635605 A	19970603	21	Method for detecting the presence of ring shaped particle tumor marker	530/412	530/403 ; 530/413 ; 530/414		Guerrero, Robert R. , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
28	US 5599291 A	19970204	16	Softening expanding ureteral stent	604/8	604/264 ; 604/544		Dalbier, Daniel J. , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
29	US 5591625 A	19970107		Transduced mesenchymal stem cells	435/366	424/93.21 ; 424/93.7 ; 435/320.1		Gerson, Stanton L. , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
30	US 5585112 A	19961217		Method of preparing gas and gaseous precursor-filled microspheres	424/450	264/4.1 ; 264/4.3 ; 424/9.51		Unger, Evan C. , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
31	US 5558646 A	19960924		Devices and methods for	604/143	601/161		Roche, Karen M.						

Ready

File View Edit Tools Window Help

Drafts

BRS:

BRS:

BRS: ("s,r" or "(sr "ls,3r") same (formoterol or foradil or efemot

ISNR:

ISNR:

BRS:

ISNR:

BRS: 1 and 3

BRS: 1 adn 3

BRS:

BRS: (vitamin\$1 or ascorb\$ or tocopheryl or tocopherol) same thicke

ISNR:

BRS:

ISNR:

Pending

Active

L1: (5596) apatite\$1 or hydroxyapatite\$1

L3: (5892) embol\$

L5: (53) and 3

Failed

(0) \$benzoate\$1

(0) 13 and 9'

(0) Sapatite\$1

Saved

Favorites

Tagged

UDC

Queue

Trash

DOCUMENT-IDENTIFIER: US 5542935 A

TITLE: Therapeutic delivery systems related applications

DATE-ISSUED: August 6, 1996

US-CL-CURRENT: 604/190,424/450,600/458

APPL-NO: 8/ 160232

DATE FILED: November 30, 1993

PARENT-CASE:

RELATED APPLICATIONS This application is a continuation-in-part of applications U.S. Ser. Nos. 08/159,687 and 08/159,674 the latter now abandoned, filed concurrently herewith on Nov. 29, 1993, which is a continuation-in-part of application U.S. Ser. No. 08/076,250, filed Jun. 11, 1993, which is a continuation-in-part of applications U.S. Ser. Nos. 08/716,899 and 07/717,084, each filed Jun. 18, 1991, the former now abandoned & the latter U.S. Pat. No. 5,228,446, which in turn are continuation-in-parts of U.S. Ser. No. 569,828, filed Aug. 20, 1990 and now U.S. Pat. No. 5,088,499, which in turn is a continuation-in-part of application U.S. Ser. No. 07/455,707, filed Dec. 22, 1989 and now abandoned, the disclosures of each of which are hereby incorporated herein by reference in their entirety.

DEPR:

Solutions of lipids or gaseous precursor-filled liposomes may be stabilized, for example, by the addition of a wide variety of viscosity modifiers, including, but not limited to carbohydrates and their phosphorylated and sulfonated derivatives; polyethers, preferably with molecular weight ranges between 400 and 8000; di- and trihydroxy alkanes and their polymers, preferably with molecular weight ranges between 800 and 8000. Glycerol propylene glycol, polyethylene glycol, polyvinyl pyrrolidone, and polyvinyl alcohol may also be useful as stabilizers in the present invention. Particles which are porous or semi-solid such as ~~hydroxyapatite~~, metal oxides and coprecipitates of gels, e.g. hyaluronic acid with calcium may be used to formulate a center or nidus to stabilize the gaseous precursors. Of course, solid particles such as limestone, zeolites, and other particles would generally be considered unsuitable for injection into the intravascular space, however, they may be quite useful for forming a nidus for the entrapment of the gaseous precursors and function as effective gastrointestinal contrast agent, e.g. for MRI or computed tomography.

DEPR:

For ~~embolization~~ of a tissue such as the kidney or the lung, the microspheres are preferably less than about 200 microns in mean outside diameter.

	U	Document ID	Issue Date	Pages	Title	Current OR	Current Ref	Retrieval C	Inventor	S	C	P	
31	<input checked="" type="checkbox"/>	US 5558646 A	19960924		Devices and methods for bone/tissue preparation	604/143	601/161 ; 604/131 ; 604/152		Roche, Karen M.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
32	<input checked="" type="checkbox"/>	US 5542935 A	19960806	66	Therapeutic delivery systems 604/190 related applications		424/450 ; 600/459		Unger, Evan C. , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
33	<input checked="" type="checkbox"/>	US 5520667 A	19960528		Methods for bone and other tissue preparation	604/290			Roche, Karen M.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Unger

File View Edit Tools Window Help

Drafts  
 BRS:  
 BRS:  
 BRS: ("s,r" or "(sr "ls,3r") same (formoterol or foradil or eformot  
 ISNR:  
 ISNR:  
 BRS:  
 ISNR:  
 BRS: 1 and 3  
 BRS: 1 adn 3  
 BRS: (vitamin\$1 or ascorb\$ or tocopheryl or tocopherol) same thicke  
 ISNR:  
 BRS:  
 ISNR:  
 Pending  
 Active  
 L1: (5596) apatite\$1 or hydroxyapatite\$1  
 L3: (5892) embol\$  
 L5: (53) 1 and 3  
 Failed  
 (0) Sbenzoate\$1  
 (0) 13 and 9'  
 (0) Sapatite\$1  
 Saved  
 Favorites  
 Tagged  
 UDC  
 Queue  
 Trash

DOCUMENT-IDENTIFIER: US 5084015 A  
 TITLE: Catheter assembly of the hypodermic embedment type  
 DATE-ISSUED: January 28, 1992  
 US-CL-CURRENT: 604/288.02, 604/185, 604/9, 604/96.01, 606/191  
 APPL-NO: 7/ 459821  
 DATE FILED: January 11, 1990  
 FOREIGN-APPL-PRIORITY-DATA:  
 FOREIGN-PRIORITY-APPL-NO: JP 63-118839  
 FOREIGN-PRIORITY-APPL-DATE: May 16, 1988  
 PCT-DATA:  
 PCT-DATE-FILED: May 15, 1989  
 PCT-APPL-NO: PCT/JP89/00490  
 PCT-371-DATE: January 11, 1990  
 PCT-102(E)-DATE: January 11, 1990  
 PCT-PUB-NO: WO89/11309  
 PCT-PUB-DATE: November 30, 1989  
 BSPR:  
 One of the intraarterial transfusion therapies is an **embolic** chemotherapy using a balloon catheter (Cancer and Chemotherapy, Vol. 11, No. 4, pages 806-813, 1984).  
 DEPR:  
 The materials of which the housing body 3A and lid 3B are formed may be any desired materials as long as they are inert to the living body, and preferably selected from resins such as polypropylene, high density polyethylene, and polycarbonate and ceramics such as alumina and **apatite**. The materials of which the housing body 3A and lid 3B are formed may be the same or different.  
 DEPR:  
 Next, the operation of the hypodermically embedable catheter assembly 1 of the invention for **embolic** chemotherapy will be described.  
 DEPR:  
 While maintaining an advantage associated with **embolic** chemotherapy that a medicament fluid in a high concentration can be directly infused to the destined site, the hypodermically embedable catheter assembly of the present invention allows therapeutic treatment to be repeatedly carried out any desired times in a simple manner with the hypodermically embedable catheter assembly kept indwelled in the body, significantly reducing the burden to the patient as compared with the prior art technique where the catheter must be inserted and

	U	Document ID	Issue Date	Pages	Title	Current OR	Current Ref	Retrieval C	Inventor	S	C	P	
44	<input checked="" type="checkbox"/>	US 5260066 A	19931109	15	Cryogel bandage containing therapeutic agent	424/447	424/443 ; 424/445 ; 424/486		Wood, Louis L. , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
45	<input checked="" type="checkbox"/>	US 5219994 A	19930615	12	Inhibitor of tissue factor activity	530/380	435/69.6		Buonassisi, Vincenzo , et al.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
46	<input checked="" type="checkbox"/>	US 5135484 A	19920804	6	Method of removing plaque from vessels	604/28	604/101.03 ; 604/22 ; 604/508		Wright, John T. M.	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
47	<input checked="" type="checkbox"/>	US 5084015 A	19920120	12	Catheter assembly of the hypodermic embedment type	604/288.02	604/195 ; 604/9 ; 604/96.01		Moriuchi, Yousuke	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
48	<input type="checkbox"/>	US 5055307 A	19911008		Slow release drug delivery	424/493	424/496		Tsuru, Sumiaki	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

imaging

File View Edit Tools Window Help

Drafts  
BRS:  
BRS:  
BRS: ("s,r" or "(sr "ls,3r") same (formoterol or foradil or eformot  
ISNR:  
ISNR:  
BRS:  
ISNR:  
BRS: 1 and 3  
BRS: 1 adn 3  
BRS:  
BRS: (vitamin51 or ascorb5 or tocopheryl or tocopherol) same thicke  
ISNR:  
BRS:  
ISNR:  
Pending  
Active  
L1: (5596) apatite\$1 or hydroxyapatite\$1  
L3: (5892) embol\$  
L5: (53) 1 and 3  
Failed  
(0) Sbenzoate\$1  
(0) 13 and 9'  
(0) Sapatite\$1  
Saved  
Favorites  
Tagged  
UDC  
Queue  
Trash

US-PAT-NO: 5055307  
DOCUMENT-IDENTIFIER: US 5055307 A  
TITLE: Slow release drug delivery granules and process for production thereof  
DATE-ISSUED: October 8, 1991  
US-CL-CURRENT: 424/493, 424/496, 424/497, 424/498, 424/499, 424/500, 424/501, 424/502  
APPL-NO: 7/ 458310  
DATE FILED: December 28, 1989  
FOREIGN-PRIORITY-APPL-NO: JP 63-335355  
FOREIGN-PRIORITY-APPL-DATE: December 29, 1988  
DEPR:  
In the practice of the present invention, the calcium phosphate compound used as a starting material of the granules is not restricted, provided that it has a Ca/P ratio of 1.3 to 1.8. A Ca/P ratio of 1.35 to 1.75 is preferable, and a Ca/P ratio of 1.4 to 1.7 is more preferably. Typical examples of the calcium phosphate compound useful in the invention include .alpha.- or .beta.-tricalcium phosphate, tetracalcium phosphate, different types of apatites such as hydroxyapatite or fluorinated apatites and the like. These calcium phosphate compounds may be used separately or in combination to form the granules. Porous granules used in the present invention can be produced in accordance with any conventional method well-known in itself, such as the method in which a foaming agent such as hydrogen peroxide is used to form pores in the granules, or the method in which the calcium phosphate compound is mixed with a particulate substance capable of being dissipated upon heating and the mixture is granulated and then heated to form the porous granules.  
DEPR:  
The porous granules used in the present invention are those fired at a temperature of 200.degree. to 1400.degree. C., preferably 500.degree. to 1300.degree. C., more preferably 700.degree. to 1200.degree. C. The firing at temperatures of less than 200.degree. C. should be avoided, because the resulting granules have a low bonding strength, and therefore can be destroyed in physiological saline or blood. The destruction of the granules means that the granules can not be practically used in the chemotherapy. On the other hand, firing temperatures over 1400.degree. C. should be also avoided, because such high temperatures cause decomposition of the calcium phosphate compound, such as hydroxyapatite.  
DEPR:  
In addition, preferably, the porous granules have a granule size of 1 .mu.m to 10 mm. When the granules are used in the transcatheter vascular embolization, they have preferably a granule size of 5 to 1000 .mu.m, because capillary blood vessels generally have a diameter of at least 5 .mu.m and catheters used to apply the granules to a blood vessel generally have an inner diameter of about 1000 .mu.m. In practice, the granules have more preferably a granule size of 5 to 500 .mu.m, since it is ideal that the granules are retained in a vessel near to a tumor tissue to be treated. The granules have most preferably a granule size of 10 to 100 .mu.m. On the other hand, when the granules are used as a filler, the size of the granules may vary depending upon the size of defects to

U	1	Document ID	Issue Date	Pages	Title	Current OR	Current IRef	Retrieval C	Inventor	S	C	P	3	4	5	6	7	8	9	0
47	P	US 5084015 A	19920128	12	Catheter assembly of the hypodermic embedment type	604/288.02	604/185 ; 604/9		Moriuchi, Yousuke											

Ready NUM

imaging

print